Adherence
Promoting therapeutic alliance in clozapine users: an exploratory randomized controlled trial [Hayward et al.] 3(3):127-132-oc

Aggression
The effects of molindone as a concomitant medication on aggressive behavior [Lindenmayer et al.] 3(4):193-200-oc

Agitation
The effects of molindone as a concomitant medication on aggressive behavior [Lindenmayer et al.] 3(4):193-200-oc

Akathisia
A brief overview of iatrogenic akathisia [Advokat] 3(4):226-236-cr

Alcohol

Anticonvulsants
The importance of screening for osteoporosis in mental health settings [Miller] 3(3):155-160-cr

Antipsychotic

The effects of olanzapine and risperidone on learning and retaining entry-level work skills [Kopelowicz et al.] 3(3):133-141-oc


The effects of molindone as a concomitant medication on aggressive behavior [Lindenmayer et al.] 3(4):193-200-oc

A pilot study to determine a prolactin threshold that identifies improved sexual functioning when switching from a prolactin-elevating to a prolactin-neutral antipsychotic [Byerly and Nakonezny] 3(4):209-216-oc

Assessment
Assessment of substance use and substance-use disorders in schizophrenia [Bennett] 3(1):50-63-cr

Brain
A review of diffusion tensor imaging in schizophrenia [Rowland et al.] 3(3):142-154-cr

Cannabis

Clozapine
An archival, follow-forward exploration of the metabolic syndrome in randomly selected, clozapine-treated patients [Josiassen et al.] 3(2):87-96-oc

Key To Abbreviations
Case Report – crep
Clinical Commentary – cc
Clinical News – cn
Comprehensive Review – cr
Consumer Perspectives – cp
CS eInterview – int
Current Clinical Trial – cct
Meeting Highlights – mh
Original Contribution – oc
The effects of olanzapine and risperidone on learning and retaining entry-level work skills [Kopelowicz et al.] 3(3):133-141-oc

Osteoporosis
The importance of screening for osteoporosis in mental health settings [Miller] 3(3):155-160-cr

PANSS
The five-factor structure of the PANSS: a critical review of its consistency across studies [Lehoux et al.] 3(2):103-110-cr

Poorly Responsive Schizophrenia
Augmentation of olanzapine by fluphenazine decanoate in poorly responsive schizophrenia [Shafti] 3(2):97-102-oc

Positive and Negative Syndrome Scale
The five-factor structure of the PANSS: a critical review of its consistency across studies [Lehoux et al.] 3(2):103-110-cr

Principal Component Analysis
The five-factor structure of the PANSS: a critical review of its consistency across studies [Lehoux et al.] 3(2):103-110-cr

Psychopharmacology
A brief overview of iatrogenic akathisia [Advokat] 3(4):226-236-cr

Psychosis

Early medication adherence and insight change in first-episode psychosis [Lepage et al.] 3(4):201-208-oc

Randomized Controlled Trial (RCT)
Promoting therapeutic alliance in clozapine users: an exploratory randomized controlled trial [Hayward et al.] 3(3):127-132-oc

Risperidone
The effects of olanzapine and risperidone on learning and retaining entry-level work skills [Kopelowicz et al.] 3(3):133-141-oc

Schizophrenia
An exploratory study of the potential prognostic usefulness of the routinely conducted computed tomography scan in patients hospitalized for a first episode of psychosis [Compton et al.] 3(1):23-30-oc

Depressive symptomatology and attributional style in patients with schizophrenia [Sanjuan et al.] 3(1):31-38-oc

Involving families in the care of persons with schizophrenia and other serious mental illnesses: history, evidence, and recommendations [Drapalski et al.] 3(1):39-49-cr

Assessment of substance use and substance-use disorders in schizophrenia [Bennett] 3(1):50-63-cr

An archival, follow-forward exploration of the metabolic syndrome in randomly selected, clozapine-treated patients [Josiassen et al.] 3(2):87-96-oc

The five-factor structure of the PANSS: a critical review of its consistency across studies [Lehoux et al.] 3(2):103-110-cr


Promoting therapeutic alliance in clozapine users: an exploratory randomized controlled trial [Hayward et al.] 3(3):127-132-oc

The effects of olanzapine and risperidone on learning and retaining entry-level work skills [Kopelowicz et al.] 3(3):133-141-oc

A review of diffusion tensor imaging in schizophrenia [Rowland et al.] 3(3):142-154-cr


The effects of molindone as a concomitant medication on aggressive behavior [Lindenmayer et al.] 3(4):193-200-oc

Early medication adherence and insight change in first-episode psychosis [Lepage et al.] 3(4):201-208-oc


Serious Mental Illness
Involving families in the care of persons with schizophrenia and other serious mental illnesses: history, evidence, and recommendations [Drapalski et al.] 3(1):39-49-cr

Side Effect(s)
A pilot study to determine a prolactin threshold that identifies improved sexual functioning when switching from a prolactin-elevating to a prolactin-neutral antipsychotic [Byerly and Nakonezny] 3(4):209-216-oc

A brief overview of iatrogenic akathisia [Advokat] 3(4):226-236-cr

Skills Training
The effects of olanzapine and risperidone on learning and retaining entry-level work skills [Kopelowicz et al.] 3(3):133-141-oc

Social Cognition
Depressive symptomatology and attributional style in patients with schizophrenia [Sanjuan et al.] 3(1):31-38-oc

Substance Abuse

Substance Use
Assessment of substance use and substance-use disorders in schizophrenia [Bennett] 3(1):50-63-cr

Substance-Use Disorders
Assessment of substance use and substance-use disorders in schizophrenia [Bennett] 3(1):50-63-cr

Tobacco
A descriptive study of nicotine, alcohol, and cannabis use

**Treatment Adherence**
Early medication adherence and insight change in first-episode psychosis [Lepage et al.] 3(4):201-208-oc

**Vocational Rehabilitation**
The effects of olanzapine and risperidone on learning and retaining entry-level work skills [Kopelowicz et al.] 3(3):133-141-oct

**White Matter**
A review of diffusion tensor imaging in schizophrenia [Rowland et al.] 3(3):142-154-crt

**Work Skills**
The effects of olanzapine and risperidone on learning and retaining entry-level work skills [Kopelowicz et al.] 3(3):133-141-oct

---

**Author Index**

**-A-**
Advokat, C.
A brief overview of iatrogenic akathisia [Advokat] 3(4):226-236-cr

Aguirre, F.
The effects of olanzapine and risperidone on learning and retaining entry-level work skills [Kopelowicz et al.] 3(3):133-141-oct

Alcantara, F.
The effects of molindone as a concomitant medication on aggressive behavior [Lindenmayer et al.] 3(4):193-200-oc

**-B-**
Beebe, L.H.
Motivating persons with schizophrenia spectrum disorders to exercise: rationale and design [Beebe et al.] 3(2):111-116-cct

Bennett, M.E.
Assessment of substance use and substance-use disorders in schizophrenia [Bennett] 3(1):50-63-cr

Bodnar, M.
Early medication adherence and insight change in first-episode psychosis [Lepage et al.] 3(4):201-208-oc

Buchy, L.
Early medication adherence and insight change in first-episode psychosis [Lepage et al.] 3(4):201-208-oc

Buckley, P.F.
Updates on long-acting injectable antipsychotics 3(1):15-cn

Update on putative cognitive-enhancing drugs 3(1):15-cn

Novel approach to antipsychotic-induced weight gain shows benefits in early clinical trials 3(1):15-cn

Phosphodiesterase inhibitors and schizophrenia treatment 3(1):16-cn

Continued concern about risks of sudden death in patients receiving antipsychotic medications 3(1):16-cn

New meta-analysis of SGAs 3(1):16-cn

Perceptual disturbances evident even in first-episode schizophrenia 3(1):16-cn

What’s the overlap between schizophrenia and bipolar: Swedish study provides clues 3(1):16-cn

Stigma still the biggest problem 3(1):17-cn

NAMI releases second “state of the states” audit 3(2):77-cn

New antipsychotic approved: iloperidone receives FDA approval 3(2):77-cn

Sertindole receives favorable FDA recommendation 3(2):77-cn

FDA panel considers antipsychotic use in younger patients 3(2):77-cn

FDA approves risperidone long-acting injection as a treatment as both monotherapy and adjunctive therapy for bipolar I disorder 3(2):78-cn

Asenapine continues under FDA review 3(2):78-cn

FDA considers quetiapine for depression and anxiety disorders 3(2):78-cn

New study information on lurasidone 3(2):78-cn

Updates on long-acting injectable olanzapine 3(2):78-cn

Gene identified for schizophrenia risk 3(2):79-cn

Mistreated children more likely to become psychotic 3(2):79-cn

New psychosis journal launched 3(2):79-cn

Updated British clinical guideline for schizophrenia 3(2):79-cn

**Burk, R.**
Motivating persons with schizophrenia spectrum disorders to exercise: rationale and design [Beebe et al.] 3(2):111-116-cct

Byerly, M.J.
A pilot study to determine a prolactin threshold that identifies improved sexual functioning when switching from a prolactin-elevating to a prolactin-neutral antipsychotic [Byerly and Nakonezny] 3(4):209-216-oc

**-C-**
Carpenter, W.T.
An interview with William T. Carpenter, Jr., MD 3(3):168-170-int

Ciranni, M.
The effects of molindone as a concomitant medication on aggressive behavior [Lindenmayer et al.] 3(4):193-200-oc

Compton, M.T.
An exploratory study of the potential prognostic usefulness of the routinely conducted computed tomography scan in patients hospitalized for a first episode of psychosis [Compton et al.] 3(1):23-30-cn
Clinical Schizophrenia & Related Psychoses January 2010 • AI 5


Cornelius, M.D.
An archival, follow-forward exploration of the metabolic syndrome in randomly selected, clozapine-treated patients [Josiassen et al.] 3(2):87-96-oc

Curtis, J.L.
An archival, follow-forward exploration of the metabolic syndrome in randomly selected, clozapine-treated patients [Josiassen et al.] 3(2):87-96-oc

David, A.
Promoting therapeutic alliance in clozapine users: an exploratory randomized controlled trial [Hayward et al.] 3(3):127-132-oc

Dessieux, O.
Motivating persons with schizophrenia spectrum disorders to exercise: rationale and design [Beebe et al.] 3(2):111-116-cct

Dixon, L.
Involving families in the care of persons with schizophrenia and other serious mental illnesses: history, evidence, and recommendations [Drapalski et al.] 3(1):39-49-cr

Drapalski, A.L.
Involving families in the care of persons with schizophrenia and other serious mental illnesses: history, evidence, and recommendations [Drapalski et al.] 3(1):39-49-cr

Esterberg, M.L.

Fedde, J.
An archival, follow-forward exploration of the metabolic syndrome in randomly selected, clozapine-treated patients [Josiassen et al.] 3(2):87-96-oc

Fenley, G.

Filmyer, D.M.
An archival, follow-forward exploration of the metabolic syndrome in randomly selected, clozapine-treated patients [Josiassen et al.] 3(2):87-96-oc

Fraguas, D.
Depressive symptomatology and attributional style in patients with schizophrenia [Sanjuan et al.] 3(1):31-38-oc

Gobeil, M-H.
The five-factor structure of the PANSS: a critical review of its consistency across studies [Lehoux et al.] 3(2):103-110-cr

Goulding, S.M.
An exploratory study of the potential prognostic usefulness of the routinely conducted computed tomography scan in patients hospitalized for a first episode of psychosis [Compton et al.] 3(1):23-30-oc


Green, N.
Promoting therapeutic alliance in clozapine users: an exploratory randomized controlled trial [Hayward et al.] 3(3):127-132-oc

Hastilow, S.
Promoting therapeutic alliance in clozapine users: an exploratory randomized controlled trial [Hayward et al.] 3(3):127-132-oc

Haworth, E.
Promoting therapeutic alliance in clozapine users: an exploratory randomized controlled trial [Hayward et al.] 3(3):127-132-oc

Hayward, P.
Promoting therapeutic alliance in clozapine users: an exploratory randomized controlled trial [Hayward et al.] 3(3):127-132-oc

Holcomb, H.H.
A review of diffusion tensor imaging in schizophrenia [Rowland et al.] 3(3):142-154-cr

Joober, R.
Early medication adherence and insight change in first-episode psychosis [Lepage et al.] 3(4):201-208-oc

Joseph, A.
An archival, follow-forward exploration of the metabolic syndrome in randomly selected, clozapine-treated patients [Josiassen et al.] 3(2):87-96-oc

Joseph, M.
An archival, follow-forward exploration of the metabolic syndrome in randomly selected, clozapine-treated patients [Josiassen et al.] 3(2):87-96-oc

Josiassen, R.C.
An archival, follow-forward exploration of the metabolic syndrome in randomly selected, clozapine-treated patients [Josiassen et al.] 3(2):87-96-oc

Kasco, M.
An archival, follow-forward exploration of the metabolic syndrome in randomly selected, clozapine-treated patients [Josiassen et al.] 3(2):87-96-oc

Khan, A.
The effects of molindone as a concomitant medication on aggressive behavior [Lindenmayer et al.] 3(4):193-200-oc

Kopelowicz, A.
The effects of olanzapine and risperidone on learning and retaining entry-level work skills [Kopelowicz et al.] 3(3):133-141-oc
Author Index

-L-
Lefebvre, A.-A.
The five-factor structure of the PANSS: a critical review of its consistency across studies [Lehoux et al.] 3(2):103-110-cr

Lehoux, C.
The five-factor structure of the PANSS: a critical review of its consistency across studies [Lehoux et al.] 3(2):103-110-cr

Leith, J.
Involving families in the care of persons with schizophrenia and other serious mental illnesses: history, evidence, and recommendations [Drapalski et al.] 3(1):39-49-cr

Lepage, M.
Early medication adherence and insight change in first-episode psychosis [Lepage et al.] 3(4):201-208-oc

Liberman, R.P.
The effects of olanzapine and risperidone on learning and retaining entry-level work skills [Kopelowicz et al.] 3(3):133-141-oc

Lindenmayer, J.P.
The effects of molindone as a concomitant medication on aggressive behavior [Lindenmayer et al.] 3(4):193-200-oc

-M-
Magallares, A.
Depressive symptomatology and attributional style in patients with schizophrenia [Sanjuan et al.] 3(1):31-38-oc

Malla, A.
Early medication adherence and insight change in first-episode psychosis [Lepage et al.] 3(4):201-208-oc

Maziade, M.
The five-factor structure of the PANSS: a critical review of its consistency across studies [Lehoux et al.] 3(2):103-110-cr

McIntyre, K.B.
Motivating persons with schizophrenia spectrum disorders to exercise: rationale and design [Beebe et al.] 3(2):111-116-cct

Merchan-Naranjo, J.
Depressive symptomatology and attributional style in patients with schizophrenia [Sanjuan et al.] 3(1):31-38-oc

Miller, B.J.
Highlights from the Twelfth Biennial International Congress on Schizophrenia Research, San Diego, CA, March 28–April 1, 2009 [Trotman and Miller] 3(2):80-86-mh

Miller, M.J.
The importance of screening for osteoporosis in mental health settings [Miller] 3(3):155-160-cr

Mintz, J.
The effects of olanzapine and risperidone on learning and retaining entry-level work skills [Kopelowicz et al.] 3(3):133-141-oc

Mullins, M.
An exploratory study of the potential prognostic usefulness of the routinely conducted computed tomography scan in patients hospitalized for a first episode of psychosis [Compton et al.] 3(1):23-30-oc

-N-
Nakonezny, P.A.
A pilot study to determine a prolactin threshold that identifies improved sexual functioning when switching from a prolactin-elevating to a prolactin-neutral antipsychotic [Byerly and Nakonezny] 3(4):209-216-oc

Nasrallah, H.A.
An interview with Henry A. Nasrallah, MD 3(1):67-70-int

Nathan, S.
An exploratory study of the potential prognostic usefulness of the routinely conducted computed tomography scan in patients hospitalized for a first episode of psychosis [Compton et al.] 3(1):23-30-oc

-P-
Parson, R.L.
An archival, follow-forward exploration of the metabolic syndrome in randomly selected, clozapine-treated patients [Josiassen et al.] 3(2):87-96-oc

Pringle, M.

Rabe-Hesketh, S.
Promoting therapeutic alliance in clozapine users: an exploratory randomized controlled trial [Hayward et al.] 3(3):127-132-oc

Resnick, B.
Motivating persons with schizophrenia spectrum disorders to exercise: rationale and design [Beebe et al.] 3(2):111-116-cct

Ressler, K.
An exploratory study of the potential prognostic usefulness of the routinely conducted computed tomography scan in patients hospitalized for a first episode of psychosis [Compton et al.] 3(1):23-30-oc

Rowand, L.M.
A review of diffusion tensor imaging in schizophrenia [Rowland et al.] 3(3):142-154-cr

Roy, M.-A.
The five-factor structure of the PANSS: a critical review of its consistency across studies [Lehoux et al.] 3(2):103-110-cr

Sanjuan, P.
Depressive symptomatology and attributional style in patients with schizophrenia [Sanjuan et al.] 3(1):31-38-oc

Seeman, M.V.

Shaffer, S.
Promoting therapeutic alliance in clozapine users: an exploratory
randomized controlled trial [Hayward et al.] 3(3):127-132-oc

Shafti, S.S.
Augmentation of olanzapine by fluphenazine decanoate in poorly responsive schizophrenia [Shafti] 3(2):97-102-oc

Shaughnessy, R.A.
An archival, follow-forward exploration of the metabolic syndrome in randomly selected, clozapine-treated patients [Josiassen et al.] 3(2):87-96-oc

Skuban, N.
An archival, follow-forward exploration of the metabolic syndrome in randomly selected, clozapine-treated patients [Josiassen et al.] 3(2):87-96-oc

Smith, K.
Motivating persons with schizophrenia spectrum disorders to exercise: rationale and design [Beebe et al.] 3(2):111-116-cct

Spieker, E.A.
A review of diffusion tensor imaging in schizophrenia [Rowland et al.] 3(3):142-154-cr

Stewart, T.

Tahir, M.S.

Tavakoli, A.
Motivating persons with schizophrenia spectrum disorders to exercise: rationale and design [Beebe et al.] 3(2):111-116-cct

Tennison, C.
Motivating persons with schizophrenia spectrum disorders to exercise: rationale and design [Beebe et al.] 3(2):111-116-cct

Thompson, N.
Promoting therapeutic alliance in clozapine users: an exploratory randomized controlled trial [Hayward et al.] 3(3):127-132-oc

Trotman, H.D.
Highlights from the Twelfth Biennial International Congress on Schizophrenia Research, San Diego, CA, March 28–April 1, 2009 [Trotman and Miller] 3(2):80-86-mh

Velligan, D.
Motivating persons with schizophrenia spectrum disorders to exercise: rationale and design [Beebe et al.] 3(2):111-116-cct

Victor, T.
An archival, follow-forward exploration of the metabolic syndrome in randomly selected, clozapine-treated patients [Josiassen et al.] 3(2):87-96-oc

Wallace, C.J.
The effects of olanzapine and risperidone on learning and retaining entry-level work skills [Kopelowicz et al.] 3(3):133-141-oc

Weinstein, J.
An archival, follow-forward exploration of the metabolic syndrome in randomly selected, clozapine-treated patients [Josiassen et al.] 3(2):87-96-oc

Whicker, N.E.
An exploratory study of the potential prognostic usefulness of the routinely conducted computed tomography scan in patients hospitalized for a first episode of psychosis [Compton et al.] 3(1):23-30-oc

Wykes, T.
Promoting therapeutic alliance in clozapine users: an exploratory randomized controlled trial [Hayward et al.] 3(3):127-132-oc